Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
gptkb:skincare_product
|
| gptkbp:associated_with |
gptkb:HIV
autoimmune diseases |
| gptkbp:can_lead_to |
Sezary syndrome
|
| gptkbp:clinical_trial |
ongoing
completed phase II phase III |
| gptkbp:first_described_by |
1806
|
| https://www.w3.org/2000/01/rdf-schema#label |
mycosis fungoides
|
| gptkbp:is_associated_with |
dermatitis
eczema psoriasis |
| gptkbp:is_characterized_by |
skin lesions
lymphadenopathy erythroderma |
| gptkbp:is_often_used_in |
adults
|
| gptkbp:live_performance |
gptkb:TNM_system
Breslow depth |
| gptkbp:occurs_in |
other skin conditions
|
| gptkbp:origin |
T-lymphocytes
|
| gptkbp:research_focus |
immune response
genetic mutations treatment efficacy |
| gptkbp:risk_factor |
age
family history male gender |
| gptkbp:social_responsibility |
rare
variable imaging tests more common in men skin biopsy incidence rate low age of onset typically 50s to 60s |
| gptkbp:symptoms |
tumors
itching plaques thickened skin skin discoloration red patches scaly patches |
| gptkbp:treatment |
radiation therapy
chemotherapy chronic condition phototherapy requires ongoing management remission possible biologic therapy |
| gptkbp:type |
gptkb:healthcare_organization
indolent lymphoma |
| gptkbp:bfsParent |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
3
|